Expand ORIC Menu
ORIC MENU

ORIC Latest Press Releases

-- June 5, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- May 27, 2026 --

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- May 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PRNewswire 8:15 PM

-- May 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC Globe Newswire 5:41 PM

-- May 4, 2026 --

ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates Globe Newswire 4:05 PM

-- May 1, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- April 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PRNewswire 10:40 PM

-- April 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC Globe Newswire 5:24 PM

-- April 22, 2026 --

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 9:56 AM

-- April 21, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC Globe Newswire 4:40 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC Globe Newswire 4:40 PM

-- April 17, 2026 --

ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting Globe Newswire 4:05 PM

-- April 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PRNewswire 10:00 AM

-- April 15, 2026 --

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm Business Wire 10:58 PM

-- April 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC Globe Newswire 5:01 PM

-- April 6, 2026 --

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 8:06 AM

-- April 3, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- March 31, 2026 --

ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile Globe Newswire 4:05 PM

-- March 27, 2026 --

ORIC Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC Globe Newswire 8:30 AM

-- March 17, 2026 --

ORIC Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting Globe Newswire 5:11 PM

-- March 6, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 23, 2026 --

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates Globe Newswire 4:05 PM

-- February 6, 2026 --

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 5, 2026 --

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM

-- January 12, 2026 --

ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes